Related Experiment Video
Updated: Jul 28, 2025
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Insights into the Role of Inflammation in the Management of Atherosclerosis
Viviane Zorzanelli Rocha1,2, Fabiana Hanna Rached1,3, Marcio Hiroshi Miname1
1Cardiopneumology Department at the Heart Institute (InCor), University of São Paulo Medical School Hospital (FMUSP), Sao Paulo, Brazil.
Insights
Inflammation plays a key role in atherosclerosis, the root cause of heart disease and stroke. Anti-inflammatory therapies show promise in reducing cardiovascular events, but more research is needed for clinical use.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Inflammation Research
Background:
- Atherosclerosis is the primary cause of global mortality from ischemic heart disease and stroke.
- Inflammation is now recognized as a central mechanism in all stages of atherosclerotic disease development.
- Recent studies, including the CANTOS trial and colchicine outcomes, provide evidence for anti-inflammatory therapy reducing cardiovascular events without affecting lipid levels.
Purpose of the Study:
- To review the evolving understanding of atherosclerosis and the role of inflammation.
- To highlight the significance of recent anti-inflammatory trials in cardiovascular risk reduction.
- To discuss the challenges and future directions for immunomodulatory strategies in clinical practice.
Main Methods:
- Review of landmark clinical trials (e.g., CANTOS) and outcome studies.
- Analysis of pre-clinical and clinical research on immunomodulatory strategies.
- Synthesis of current evidence on anti-inflammatory therapies for cardiovascular risk.
Main Results:
- Anti-inflammatory therapies, like those targeting IL-1β, can reduce cardiovascular events.
- These therapies demonstrate efficacy independent of their effects on lipid profiles.
- The findings support a paradigm shift towards targeting inflammation in cardiovascular disease prevention.
Conclusions:
- Landmark studies confirm the efficacy of anti-inflammatory treatments in reducing cardiovascular events.
- Significant challenges remain in selecting optimal therapies and patient populations for immunomodulatory strategies.
- Further research is essential to integrate anti-inflammatory agents into routine clinical practice for managing atherosclerotic disease.
Abstract:
Atherosclerosis is the biological basis of ischemic heart disease and ischemic stroke, the leading causes of death in the world. After decades of studies, the understanding of atherosclerosis has evolved dramatically, and inflammation has been recognized as one of the most relevant pillars in all phases of atherosclerotic disease. Nevertheless, only recently, the trial CANTOS, and subsequent outcome studies with colchicine, finally provided proof-of-concept evidence that anti-inflammatory therapies were able to reduce cardiovascular events with no influence on lipid levels. These landmark studies inaugurated an era of clinical and pre-clinical studies of immunomodulatory strategies focused on reduction of cardiovascular risk. Although there are promising results in the field, selection of the most appropriate immunomodulatory therapy and identification of patients who could benefit the most, are still enormous challenges. Further research is imperative before we can finally advance towards regular use of anti-inflammatory agents to reduce atherosclerotic events in our clinical practice.
Related Concept Videos
01:26Atherosclerosis III: Management
01:38Inflammation
01:30Atherosclerosis I: Introduction
01:23Atherosclerosis IV: Nursing Management
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:30Coronary Artery Disease I: Introduction